<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70445">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837641</url>
  </required_header>
  <id_info>
    <org_study_id>15082</org_study_id>
    <secondary_id>I5T-MC-AACC</secondary_id>
    <nct_id>NCT01837641</nct_id>
  </id_info>
  <brief_title>A Study of LY3002813 in Participants With Alzheimer's Disease</brief_title>
  <official_title>A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety of LY3002813 by looking at adverse events. The study will
      also look at the effect the body has on LY3002813. Study participants will have mild
      cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.

      There will be six groups of study participants.  Five groups will receive a single dose of
      LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo
      given as an injection into a vein. Approximately 12 weeks will pass between the single dose
      and the first multiple dose. One group of participants will receive a single dose of
      LY3002813 given as an injection under the skin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Day 1 up to Day 253</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813</measure>
    <time_frame>Predose up to Day 253</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813</measure>
    <time_frame>Predose up to Day 253</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Single then multiple</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given once, then every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 mg/kg LY3002813 given once subcutaneously (SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3002813-IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 1 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 3 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 10 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3002183-SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3002813-SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo-Single then multiple</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or
             mild-to-moderate AD

          -  Men or nonfertile women, at least 50 years of age. Nonfertile is defined as
             hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year

          -  Have a caregiver/study informant who provides a separate written informed consent to
             participate

          -  Have adequate vision and hearing for neuropsychological testing in the opinion of the
             investigator

          -  Positive florbetapir scan

        Exclusion Criteria:

          -  History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous
             malformation, or carotid artery occlusion, or stroke or epilepsy

          -  Do not have a reliable caregiver/study informant who is in frequent contact with the
             participant, who will accompany the participant to the office and/or be available by
             telephone at designated times, and will monitor administration of prescribed
             medications

          -  Have any contraindications for magnetic resonance imaging (MRI) studies, including
             claustrophobia, the presence of contraindicated metal (ferromagnetic) implants,
             cardiac pacemaker

          -  Are being monitored for radiation due to occupational exposure to ionized radiation,
             or exposure to ionizing radiation within last 12 months from an investigational study

          -  Have allergies to humanized monoclonal antibodies, including proteins and
             diphenhydramine, epinephrine, and methylprednisolone

          -  Have gamma globulin therapy within the last year

          -  Previously dosed in any other study investigating active immunization against amyloid
             beta (Aβ)

          -  Previously dosed in any other study investigating passive immunization against Aβ
             within the last 6 months

          -  History within the past 5 years of a primary or recurrent malignant disease with the
             exception of resected cutaneous squamous cell carcinoma in situ, basal cell
             carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal
             prostate-specific antigen post resection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sumida-Ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>111-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
